-
1 Comment
Nkarta, Inc is currently in a long term downtrend where the price is trading 25.5% below its 200 day moving average.
From a valuation standpoint, the stock is 74562.7% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1000000.0.
Based on the above factors, Nkarta, Inc gets an overall score of 0/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US65487U1088 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 158M |
|---|---|
| Beta | 0.84 |
| PE Ratio | None |
| Target Price | 13.4 |
| Dividend Yield | None |
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NKTX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
